Bone replacements, human tissue and prosthetics are being created by 3-D bioprinters. The science will soon be used to customize drugs.» Read More
Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.
We've known that Merck has been testing its cervical cancer vaccine Gardasil on young men (16-23 years old). The company says major data on those clinical trials are expected next year and could help Merck win FDA approval of the shots for males as well as females. The first-of-its-kind product has already sparked a sociopolitical controversy with its recommended use for young women. Imagine the brouhaha if or when Merck starts selling it for young men.
British animal health authorities imposed restrictions around a second site amid fears that the outbreak of foot and mouth disease had spread from an initial control zone.
If things DO get worse out there, you're going to need a stock that is completely insensitive to the state of the economy. In the end, our narcissism could be what saves our portfolios.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
In very early trading MRK shares are rallying this morning on the wings of an upgrade at Cowen & Co. by analyst Steve Scala from Neutral to Outperform. He's been at a Neutral since a year and one month ago when the stock was sitting in the 30s. Today it's in the low 50s.
Stocks ended a volatile week with a late selloff, erasing any hope for a quick recovery from last week's trouncing.
Despite predictions that the Dow would be down big, the index posted a triple-digit gain for the second day in a row. So what's the deal?Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
This morning we learned that the FDA has issued another "approvable" letter to Pozen and GlaxoSmithKline for their migraine drug Trexima over safety concerns. POZN shares are down big. The company has scheduled a conference call for 11 a.m. ET. This is the third regulatory stumbling block for this drug and puts it on a timeline now where it could end up competing...
Stocks rose sharply in the final minutes of trading, with the Dow posting a triple-digit gain, as bargain hunters snapped up beaten down shares after credit jitters weighed on the markets all session. "At some point we have to look at the recent downturn as being slightly overdone," Arthur Hogan, managing director at Jefferies, told CNBC.com.
With stocks in rally mode, it's appropriate to drill down for answers as well as take a look at some key sectors.
As the push for universal health care in the U.S. heats up on Capitol Hill, market experts say generic drug stocks and pharmaceutical distributors should perform well, while the hit to big pharma may not be as bad as some anticipate.
Stocks suffer their worst weekly declines in more than four years as worries about credit and lending undermine investor confidence.
A new study shows lowering cholesterol could increase the risk of cancer. The Journal of the American College of Cardiology reports that researchers observed as much as triple the incidence of cancer among patients who lowered their bad or LDL cholesterol using the popular drugs known as statins.
Stocks ended with solid gains on Monday as investors were encouraged by solid earnings reports and the return of brisk mergers and acquisitions activity. "We definitely had a lot of good news today," said Charles Rotblut, senior market analyst at Zacks.com. "I think we definitely could see the Dow at new highs before the week is over."
Corporate takeovers in the tech sector and earnings news were some of the catalysts behind the most actively traded stocks on Monday.
After a disappointing week for big pharma earnings, Merck and Schering-Plough start the second-half of the sector's reporting season with a bang. Both companies beat the Street on the top and bottom lines. Merck also raised its full-year earnings guidance to boot. And investors love it. Look at the huge move in the Dow component.
Schering-Plough on Monday said second-quarter earnings more than doubled, driven by growing demand for its Zetia and Vytorin cholesterol drugs and its treatments for arthritis and allergies.
Mergers and acquisitions and a generous portion of quarterly earnings along with OPEC news is turning the stock market picture back to the plus side after Friday's selloff, though looming in the background are credit market concerns.
Merck said Monday that quarterly earnings rose 12% on strong demand for its newer vaccines and medicines, and raised its 2007 profit forecast, sending its shares up 4%.
With a couple of exceptions the pharma earnings season has failed to impress Wall Street, so far. Take a look at the one week performance of the Amex Pharmaceutical Index versus the Dow. Next week there's no let-up. Right out of the gate on Monday morning Merck and Schering-Plough report.